Male Infertility. Diseases of male genital organs,Male infertility
Conditions
Interventions
Intervention 1: In control group: receiving pentoxifylline, patients will receive 800mg of pentoxifylline granules +placebo powder daily in the form of 5 capsules in morning, noon, night for 3 mon
Treatment - Drugs
In control group: receiving pentoxifylline, patients will receive 800mg of pentoxifylline granules +placebo powder daily in the form of 5 capsules in morning, noon, night for 3 months
In receiving traditional medicine product group(Withania somnifera ), patients will receive 5 g of this product daily in the form of 5 capsules in morning,noon, night for 3 months
Sponsors
Vice chancellor for research,Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria:Patient satisfaction? Men 18-45 years? Infertility for at least one year with unexplained Oligo+/- astheno +/- teratozoospermia according to WHO criteria? Nonsmoking and nonaddiction to alcohol and drugs? No azospermia? No infections, No genital anatomical abnormalities? No risk of varicocele? No history of surgery on the genital tract? No Systemic diseases ( cancer, thyroid diseases, liver and gall bladder diseases, renal failure, diabetes, uncontrolled hypertension, cerebral hemorrhage , retina bleeding, etc)? No unilateral testicular atrophy? No history of taking chemotherapy, corticosteroid, anticoagulation,testosterone, antiandrogen. Exclusion criteria: Smoking or any kind of drug abuse during the study? Intaking any other chemical or herbal infertility drug during the study? Make any side effects from medication? The need for other interventions and surgery during the study? The reluctance of patients to continue.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sperm count. Timepoint: At the begining of the trial,90 days after the intervention. Method of measurement: Sperm analysis.;Sperm motility. Timepoint: At the begining of the trial,90 days after the intervention. Method of measurement: Semen analysis.;Sperm morphology. Timepoint: At the begining of the trial,90 days after the intervention. Method of measurement: Semen analysis.;Semen volume. Timepoint: At the begining of the trial,90 days after the intervention. Method of measurement: Semen analysis. | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine the potential adverse events resulting from treatment process in patients in the intervention groups. Timepoint: during the study. Method of measurement: questionnaire-Observation-reportage. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRamin Nasimi Doost Azgomi
School of Traditional Medicine, Tabriz University of Medical Sciences
Outcome results
None listed